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Interleukin (IL)-25, a cytokine active in inflammatory
processes and production of proinflammatory cytokines,
is secreted by mammary epithelial non-malignant cells
and induces apoptosis in tumour cells by differential
expression of its receptor IL-17RB, highly expressed in
malignant cells and lower expressed in non-malignant
epithelial cells. It is known that another ligand (IL-17B)
compete for the same site of action in tumour cells,
contributing to its tumorigenic potential. The melatonin
hormone acts in several activities, among them the
immune system regulation, proliferation, differentiation
and apoptosis process in tumour cells. The aim of this
study was to evaluate the effects of treatment with
IL-25, silencing gene (siRNA) of cytokine IL-17B and
melatonin in human mammary tumour cells for the
control of cell proliferation and induction of apoptosis.
Non-metastatic mammary tumour cells (MCF-7), meta-
static (MDA-MB-231) and a human normal mammary
epithelial cells (MCF-10A) were cultured and divided
into five treatment groups: group I control, group II
treated with IL-25 protein, group III treated with siRNA
IL-17B, group IV treated with melatonin and group V
joint treatments. The gene silencing was standardised by
real-time PCR (qPCR), cell viability assessed by MTT
assay and protein expression of caspase-3, apoptotic
marker, by immunocytochemistry and subsequent quan-
tification by optical densitometry. After 24 hours of
incubation with IL-25 at concentrations of 1, 10 and
50 ng/mL was found a significant decrease in cell viabi-
lity at 1 ng/mL (38.5 % for MCF-7 cells and 74.0 % for
MDA-MB-231 cells; p<0.05) compared with control
group, and increased expression of caspase-3 (p<0.001)
in both lineage cells. The treatment with siRNA IL-17B
at 10nM significantly decreased cell viability (80.0% for
MCF-7 cells and 86.0% for MDA-MB-231 cells, p<0.05),
and showed a slight increase in the expression of cas-
pase-3. When treated with melatonin at concentrations
from 0.001 to 1 mM was observed a significant decreased
in cell viability at 1 mM (70.0% for MCF-7 cells and
41.0% for MDA-MB-231 cells; p<0.05) and high expres-
sion of caspase-3 (p<0.001) in both lineage cells. For
MCF-10A cells, there was no decrease in cell viability to
treatments proposed, enabling the use of these therapeu-
tic agents. The joint treatments showed synergic action
in reducing the cell viability and induction apoptosis.
Our results reinforce the anti-proliferative properties of
these agents in breast cancer, establishing new therapeu-
tic strategies. In addition, understanding the role of these
factors in immune modulating highlights the growing
connection between the contribution of the immune sys-
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